Welcome to our dedicated page for Regenerative Medical Technology Group SEC filings (Ticker: RMTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the numbers behind Regenerative Medical Technology Group’s stem-cell clinics and exosome product sales? This dedicated page brings every RMTG SEC filing explained simply, guiding you from first click to final footnote. Whether you need the RMTG quarterly earnings report 10-Q filing or want to monitor RMTG insider trading Form 4 transactions, it’s all here and refreshed in real-time as documents hit EDGAR.
Stock Titan’s AI steps in the moment a disclosure appears. Our engine delivers plain-language summaries, highlights segment revenue tied to new regenerative therapies, and flags risk factors—so understanding RMTG SEC documents with AI takes minutes, not hours. Navigate with confidence through:
- 10-K insights: RMTG annual report 10-K simplified pinpoints R&D spending, clinic expansion costs, and product approval timelines.
- 10-Q snapshots: Real-time RMTG earnings report filing analysis compares quarter-over-quarter treatment volumes.
- 8-K alerts: RMTG 8-K material events explained—from new Dubai clinic openings to distribution agreements.
- Form 4 tracking: Get RMTG Form 4 insider transactions real-time and review RMTG executive stock transactions Form 4 before market movers notice.
- DEF 14A coverage: Explore the RMTG proxy statement executive compensation details to see how leadership is rewarded for clinic growth.
Professionals use these filings to compare training-program margins, gauge regulatory risks, and spot insider buying patterns. With AI-powered summaries, keyword search, and instant email alerts, you’ll never miss a filing that could reshape the regenerative medicine landscape.
Regenerative Medical Technology Group Inc. (RMTG) reports higher revenue but deepening losses for the nine months ended September 30, 2025. Revenue rose to $3,528,393 from $2,596,671, driven entirely by Global Stem Cells Group, with growth in training, product supplies, and patient procedures. Cost of revenue increased, but the company still generated gross profit of $2,031,283.
Operating expenses climbed to $2,592,171, and heavy interest and financing costs pushed total other expense to $5,858,678, resulting in a net loss of $6,419,566 versus $4,924,785 a year earlier. The balance sheet shows assets of $4,519,827 against total liabilities of $34,574,268 and a stockholders’ deficit of $30,054,441. The company discloses a working capital deficit of $15,762,714 and an accumulated deficit of $73,972,668 and states there is substantial doubt about its ability to continue as a going concern.
Regenerative Medical Technology Group Inc. (RMTG) filed a Form 12b-25 (NT 10-Q) for its Quarterly Report for the period ended September 30, 2025.
The company says it could not, without unreasonable effort or expense, complete the financial statements and related disclosures. It expects to file the Form 10-Q within the five-day grace period provided by Rule 12b-25.
FAQ
What is the current stock price of Regenerative Medical Technology Group (RMTG)?
What is the market cap of Regenerative Medical Technology Group (RMTG)?
